An escalating dose study to assess the safety, tolerability and immunogenicity of a Herpes Simplex Virus DNA vaccine, COR-1.
about
DNA Vaccine Encoding HPV16 Oncogenes E6 and E7 Induces Potent Cell-mediated and Humoral Immunity Which Protects in Tumor Challenge and Drives E7-expressing Skin Graft RejectionFuture prospects for new vaccines against sexually transmitted infections.Vaccination to Reduce Reactivation of Herpes Simplex Virus Type 2.Biologic interactions between HSV-2 and HIV-1 and possible implications for HSV vaccine development.
P2860
An escalating dose study to assess the safety, tolerability and immunogenicity of a Herpes Simplex Virus DNA vaccine, COR-1.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 31 August 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
An escalating dose study to as ...... plex Virus DNA vaccine, COR-1.
@en
An escalating dose study to as ...... plex Virus DNA vaccine, COR-1.
@nl
type
label
An escalating dose study to as ...... plex Virus DNA vaccine, COR-1.
@en
An escalating dose study to as ...... plex Virus DNA vaccine, COR-1.
@nl
prefLabel
An escalating dose study to as ...... plex Virus DNA vaccine, COR-1.
@en
An escalating dose study to as ...... plex Virus DNA vaccine, COR-1.
@nl
P2093
P2860
P50
P1476
An escalating dose study to as ...... mplex Virus DNA vaccine, COR-1
@en
P2093
P2860
P304
P356
10.1080/21645515.2016.1221872
P577
2016-12-01T00:00:00Z